PHOENIX – October 21, 2019 /Canna Newswire/ – This week Cannasphere Biotech introduced a lineup of nanoliposomal CBD beverage powers in three refreshing flavors, powered by the company’s patent pending Lipofusion™ delivery technologies. The initial 3 flavors obtainable are:
- Passionfruit Citrus
- Ginger Lemonade
- Blueberry Chill
“The flavor possibilities are practically limitless and these Lipofusion CBD beverage powders build a refreshing, enjoyable CBD expertise.” mentioned Star Simmons, president of Cannasphere. “Consumers yearn for the promises that CBD holds so they place up with unpalatable tinctures or powders, or add extra capsules to their pill routine. That is not needed any longer. Just add any of these good-tasting CBD beverage powders to water, shake, sip and love.”
According to Simmons, these flavored CBD beverage powders, powered by Lipofusion, are obtainable for private label and can be packaged in practical single-serving stick packs or pouches with 30 or 60 servings, containing 10 or 20 mg of nanoliposomal CBD per serving. The organization also delivers custom formulation solutions for brands that would like to create their personal custom flavors and probably add other synergistic actives, such as Vitamin C, curcumin, or melatonin, that combine nicely with CBD.
“While the industry is becoming crowded with ineffectual CBD items, it is critical to set your brand apart by providing CBD items that get outcomes. Our Lipofusion delivery technologies makes it possible for CBD brands to do that,” mentioned Andrew Wood, biochemistry advisor for Cannasphere. “Lipofusion technologies utilizes nanoliposomal encapsulation to facilitate fast onset and sustained release to guarantee customers truly really feel the distinction and love lasting positive aspects.”
In truth, Forbes published an short article on October 1st showcasing a current pharmacokinetic study demonstrating that nanoliposomes are the most optimal way to provide CBD to the human physique. Cannasphere’s hemp-derived, water-soluble CBD items are broad spectrum and formulated making use of patent pending nanoliposomal delivery technologies referred to as Lipofusion to optimize bioavailability and assimilation of cannabinoids at the cellular level. Learn extra at www.lipofusion.com.
“When customers get exceptional outcomes, they grow to be quite loyal to a specific brand—they may well even grow to be brand evangelists. That translates into repeat sales as nicely as word-of-mouth buzz,” added Simmons.
To acquire no cost samples of every flavor take a look at: https://www.cannaspherebiotech.com/samples/
About Cannasphere Biotech
Cannasphere Biotech combines the energy of Cannabidiol (CBD) with its proprietary major edge Lipofusion delivery technologies to maximize efficacy and provide exceptional, trustworthy positive aspects. The organization delivers unflavored manufacturing-prepared Lipofusion CBD powder and a range of private-label CBD items such as flavored CBD beverage powders. For extra info please take a look at www.cannaspherebiotech.com.
About Cannabidiol (CBD)
According to CBDProject.com, the excitement about Cannabidiol (CBD) and its several well being positive aspects is steadily rising worldwide. Scientific and clinical investigation worldwide underscores the possible of CBD as an helpful medicinal agent intended to help wellbeing. CBD is at present getting studied as an adjunct therapy for a wide variety of circumstances such as arthritis, diabetes, alcoholism, MS, chronic discomfort, schizophrenia, PTSD, depression, antibiotic-resistant infections, epilepsy, and other neurological problems.[1,2,3] CBD has demonstrable neuroprotective properties and is a concentrate for anti-cancer investigation at many US and international academic investigation centers. [1,2,3,4]
Cannabis Cannabinoid Res. 2017 two(1): 139–154.Published on-line 2017 Jun 1. doi: 10.1089/can.2016.0034
Perm J. 2019 23: 18-041.Published on-line 2019 Jan 7. doi: 10.7812/TPP/18-041
Cannabis Cannabinoid Res. 2018 three(1): 152–161.Published on-line 2018 Jul 1. doi: 10.1089/can.2018.0006
Surg Neurol Int. 2018 9: 91.Published on-line 2018 Apr 26. doi: 10.4103/sni.sni_45_18
# CNW #
Media Get in touch with: